Gout disease-related years lived with disability in the North Africa and Middle East countries: a systematic analysis of the GBD study 1990–2019
Authors:
- Moloud PayabMPMoloud Payab
- Sahar Saeedi MoghaddamSMSahar Saeedi Moghaddam
- Yasaman SharifiYSYasaman Sharifi
- Farshad SharifiFSFarshad Sharifi
- Mahbube EbrahimpurMEMahbube Ebrahimpur
- Alireza HadizadehAHAlireza Hadizadeh
- Zahra EsfahaniZEZahra Esfahani
- Pouya EbrahimiPEPouya Ebrahimi
- Pedram RamezaniPRPedram Ramezani
- Zahra Hoseini TavassolZTZahra Hoseini Tavassol
- Ali GhanbariAGAli Ghanbari
- Parnian ShobeiriPSParnian Shobeiri
- 13 October 2025
- journal article
- review article
- Published by Springer Nature in Rheumatology International
- Vol. 45 (11) , 250
Abstract
The purpose of this study is to describe the changes in the age-standardized prevalence rate, incidence rate, and years lived with disability (YLDs) rate for gout disease and the associated risk factors in 21 North Africa and Middle East (NAME) countries from 1990 to 2019 based on age, gender, and socio-demographic index (SDI). From 1990 to 2019, the Global Burden of Disease (GBD) team performed a comprehensive systematic review of databases and disease-modeled analysis in the NAME countries. Age-standardized prevalence, incidence, and YLD rates, as well as the attributed burden to risk factors (high body mass index (BMI) and kidney dysfunction), were reported with 95% uncertainty intervals (UIs). The age-standardized YLDs estimated in 2019 and 1990 were 14.2 (95% UI 8.9–20.4) and 15.8 (10.0–22.7) per 100,000 populations, respectively, with an increase of 11.7% (7.1–16.4%) from 1990. The health indicators were all reported to be higher among males. The three countries with higher SDI that had the highest age-standardized YLDs rate in 2019 were Qatar (22.5 [14.5–32.7]), the United Arab Emirates (20.5 [12.9–29.9]), and Kuwait (19.0 [11.7–27.6]), while YLDs in 2019 attributable to high BMI and kidney dysfunction were estimated to be 7.2 (3.8–12.2) and 3.7 (2.3–5.5) per 100,000, respectively. According to our findings, the burden of gout in the NAME is higher than the reported global average and has risen from 1990 to 2019. Despite advances in gout treatment, NAME countries should prioritize preventive interventions to manage the disease’s burden. Gout is the most common type of inflammatory arthropathy, and there have been no specific reports of this disease burden in the NAME countries, which account for nearly 8% of the global population. This report estimated that age-standardized YLDs increased by 11.7% (7.1%–16.4%) from 1990 to 2019 in this region. Consequently, these countries have to prioritize preventive interventions to manage the disease’s burden.Keywords
This publication has 40 references indexed in Scilit:
- Epidemiology of gout in women: Fifty‐two–year followup of a prospective cohortArthritis & Rheumatism, 2010
- Prevalence and Trends in Obesity Among US Adults, 1999-2008JAMA, 2010
- Metabolic syndrome-related conditions among people with and without gout: prevalence and resource useCurrent Medical Research and Opinion, 2007
- Prevalence of the metabolic syndrome in patients with gout: The Third National Health and Nutrition Examination SurveyArthritis Care & Research, 2007
- Hyperuricemia and gout: new insights into pathogenesis and treatment.2007
- Obesity, Weight Change, Hypertension, Diuretic Use, and Risk of Gout in MenArchives of internal medicine (1960), 2005
- Purine-Rich Foods, Dairy and Protein Intake, and the Risk of Gout in MenNew England Journal of Medicine, 2004
- Female gout. Clinical spectrum and uric acid metabolismArchives of internal medicine (1960), 1991
- Asymptomatic hyperuricemia. Risks and consequences in the normative aging studyThe American Journal of Medicine, 1987
- Preliminary criteria for the classification of the acute arthritis of primary goutArthritis & Rheumatism, 1977